David W. Dougherty, MD, MBA, discusses telemedicine in oncology after emergence of COVID-19.
David W. Dougherty, MD
Advertisement
Articles by David W. Dougherty, MD
David W. Dougherty, MD, discusses how cancer centers can move forward following the negative effects caused by the COVID-19 pandemic.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
2
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
3
Beyond SC Daratumumab: Emerging Therapeutic Approaches for Smoldering Myeloma
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
